2026 Eastern Food Allergy & Comorbidity Conference (EFACC)

January 8, 2026 to January 11, 2026

The 2026 Eastern Food Allergy & Comorbidity Conference (EFACC) will provide attendees with knowledge regarding novel food allergy developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology, particularly as it relates to food allergies and associated allergic comorbidities. In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core learning objectives relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision-making concerning diagnostic and treatment strategies for patients food allergies and comorbid allergic diseases. Topics of discussion will include food allergy prevention, food allergy immunotherapy, asthma, atopic dermatitis, eosinophilic esophagitis and shared decision making.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Eastern Food Allergy & Comorbidity Conference (EFACC). The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 16.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 16.75 contact hours.

No commercial support was received for this activity.

Target Audience

Allergist-immunologists in clinical practice
Fellows in Training (FIT) A-I programs
Allied health professionals in the field of allergy-immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
1) Formulate an appropriate treatment strategy for eosinophilic esophagitis
2) Compare and contrast the risks and benefits of various forms of food immunotherapy
3) Synthesize a treatment plan for intermittent, mild/moderate, and severe persistent asthma as comorbidities of food allergy
4) Assess atopic dermatitis as a comorbidity of food allergy
5) Utilize and optimally perform shared decision-making in food allergy management
6) Integrate anaphylaxis preparedness and treatment in food allergy management

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 16.75 AMA PRA Category 1 Credit™
  • 16.75 Attendance
  • 16.75 CBRN
Course opens: 
01/08/2026
Course expires: 
12/31/2027
Event starts: 
01/08/2026 - 12:00am CST
Event ends: 
01/11/2026 - 12:00pm CST
Add to calendar: 
Rating: 
0

Eastern Food Allergy Comorbidity Conference
January 8-11, 2026
Eau Palm Beach Resort & Spa, Manalapan FL

All CME sessions will be held in the Grand Ballroom, Salon I.

Thursday, January 8
3:00 - 3:15 PM Welcome and meeting overview, Russell Settipane, MD, Katherine Anagnostou, MD

3:15 - 3:30 PM Journal of Food Allergy: Year-in-review, Katherine Anagnostou, MD

3:30 - 4:00 PM The multiple facets of milk allergy in infants, Jonathan Tam, MD

4:00 - 4:30 PM The confusing landscape of wheat hypersensitivities: Making the correct diagnosis, Sami Bahna, MD

4:30 - 4:45 PM Panel Discussion: Q & A

4:45 - 5:15 PM A review of the 2025 food allergy literature: What can new evidence do for my practice?, Elissa Abrams, MD

5:15 - 5:45 PM All about food allergy therapies: What options should I be offering my patients in 2026?, Julia Upton, MD

5:45 - 6:15 PM Atopic Dermatitis: Quantifying patient suffering, Jonathan Tam, MD

6:15 - 6:30 PM Panel Discussion: Q & A

Friday, January 9
7:45 - 8:15 AM The role of AI in food allergy: How to navigate novel tools, Nicholas Rider, DO

8:15 - 8:45 AM Practical SLIT in food allergy: What is happening in the real world?, Edmond Chan, MD

8:45 - 8:55 AM Panel Discussion: Q & A

8:55 - 10:00 AM PBL: A 7-year-old with food allergies and comorbid asthma, Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD

10:00 - 10:45 AM Coffee Break - Visit exhibits and posters,  Grand Ballroom, Salon III

10:45 - 11:15 AM Eosinophilia and food allergy: A practical approach, Richard Wasserman, MD

11:15 - 11:45 AM When and how to address significantly elevated IgE levels in food allergy, Julia Upton, MD

11:45 AM - 12:15 PM Food allergy and asthma: Management overview, Wanda Phipatanakul, MD

12:15 - 12:30 PM Panel Discussion: Q & A

1:25 - 1:55 PM Oral food challenges: A practical approach, Roxanne Oriel, MD

1:55 - 2:20 PM Biologics for asthma: What to use and when?, Wanda Phipatanakul, MD

2:20 - 2:50 PM Safety of biologics in food allergy: What our patients need to know, Shahzad Mustafa, MD

2:50 - 3:00 PM Panel Discussion: Q & A

Saturday, January 10
7:45 - 8:15 AM Adult food allergy, Shahzad Mustafa, MD

8:15 - 8:45 AM Food pollen syndrome: An overview, Edmond Chan, MD

8:45 - 8:55 AM Panel Discussion: Q & A

8:55 - 10:00 AM PBL: A 26-year-old with food allergy and recurrent anaphylaxis, Ray Davis, MD, Don Bukstein, MD, Russell Settipane, MD

10:00 - 10:45 AM Coffee Break - Visit exhibits and posters, Not for CME / Grand Ballroom, Salon III

10:45 - 11:15 AM Anaphylaxis case management, Elissa Abrams, MD

11:15 - 11:30 AM Benefits of “watching and waiting” after epinephrine is administered, Richard Wasserman, MD

11:30 - 11:45 AM Risks of “watching and waiting” after epinephrine is administered, Sami Bahna, MD

11:45 AM - 12:15 PM Choosing the right epinephrine device for the right food-allergic patient, Matthew Greenhawt, MD

12:15 - 12:40 PM Panel Discussion: Q & A (with Abrams, Wasserman, Bahna, Greenhawt, and Scott Commins, MD)

1:35 - 2:05 PM An updated action plan for anaphylaxis, Katherine Anagnostou, MD

2:05 - 2:30 PM Discussing the omalizumab option in a shared decision-making conversation with your food allergy patients, Jonathan Tam, MD

2:30 - 3:00 PM Navigating EoE therapies: A practical approach, Matthew Greenhawt, MD

3:00 - 3:10 PM Panel Discussion: Q & A

Sunday, January 11
8:15 - 8:45 AM Addressing food allergy misconceptions, Tim Buckey, MD

8:45 - 9:15 AM Food allergy OIT: What happens 5 and 10 years down the line?, Katherine Anagnostou, MD

9:15 - 9:45 AM Mild food allergy and thresholds, Roxanne Oriel, MD

9:45 - 10:15 AM EoE: Managing challenging cases, Tim Buckey, MD

10:15 - 10:30 AM Panel Discussion: Q & A
 

All relevant financial relationships with ineligible companies have been mitigated.

Katherine Anagnostou, MD - Planner, Speaker
Researcher - ALK, Aquestive, Novartis

Don Bukstein, MD - Facilitator
Speaker - Sanofi and Regeneron

Edmond Chan, MD - Speaker
Advisor - ALK, Novartis, Sanofi, Viatris
Researcher - DBV Technologies, ALK-Abello

Scott Commins, MD - Panelist
Advisor/Speaker – Genentech, Regeneron

Ray Davis, MD - Facilitator
Consultant - Regeneron, Sanofi, Grifols, AstraZeneca

Sandra Gawchik, MD - Moderator
Advisor - AstraZeneca
Speaker - AstraZeneca, Novartis

Matthew Greenhawt, MD - Speaker
Advisor - Nutricia, DBV, Novartis, Aquestive, Bryn, ALK 
Speaker - ARS, Genentech

William Greisner, MD - Planner, Moderator
Independent Contractor - GSK, AstraZeneca, TEVA, Regeneron

Shahzad Mustafa, MD - Speaker
Speaker - Genentech, GSK, AstraZeneca, Regeneron/Sanofi, CSL Behring, ARS Pharma

Roxanne Oriel, MD - Speaker
Researcher - ALK, Allergy Therapeutics, DBV 
Speaker - ARS Pharma, Genentech

Wanda Phipatanakul, MD - Speaker
Advisor, Speaker - Genentech, Novartis, Regeneron, Sanofi, AstraZeneca

Russell Settipane, MD - Planner, Speaker, Moderator, Reviewer
Advisor - AstraZeneca, GSK
Independent Contractor - AstraZeneca, Genentech, GSK, Regeneron
Speaker - Amgen, AstraZeneca, Genentech, GSK, Grifols, Novartis, Regeneron, Sanofi

Jonathan Tam, MD - Speaker
Researcher - DBV, Novartis
Speaker - ARS Pharma

Julia Upton, MD - Speaker
Advisor - DBV Technologies, ALK Abello, Pfizer, Pharming
Consultant - Viatris
Researcher - DBV Technologies, ALK Abello, Sanofi/Regeneron RAPT, Aquestive, Novartis 

Richard Wasserman, MD - Speaker
Consultant, Speaker – Grifols


The following have no relevant financial relationships with ineligible companies:

Elissa Abrams, MD - Speaker
Sami Bahna, MD - Speaker
Tim Buckey, MD - Speaker
William Corrao, MD - Planner, Moderator, Reviewer
Jill Courcier - Coordinator
Katelyn Keedy, RN - Planner
Ginny Loiselle - Coordinator
Nicolas Rider, DO - Speaker
Robert Settipane, MD - Planner, Moderator, Reviewer

Available Credit

  • 16.75 AMA PRA Category 1 Credit™
  • 16.75 Attendance
  • 16.75 CBRN
Please login or create an account to take this course.